Abstract 555P
Background
Approximately half of non-small cell lung cancer (NSCLC) patients are diagnosed at a metastatic stage. Molecular testing is vital for identifying druggable mutations in these patients. This prospective study aimed to assess the quality of life (QoL) of these patients and differences in QoL between patients with or without druggable mutations.
Methods
Patients newly diagnosed with stage IV NSCLC after March 2021 from the seven public oncology centres in Hong Kong were eligible. Mutation profiling was performed using next-generation sequencing with FoundationOne CDx. QoL assessments were conducted at baseline and then at 3, 6, 9, and 12 months using validated EORTC QLQ-C30 and EQ-5D-5L questionnaires.
Results
A total of 580 patients were included. Statistically significant changes in various aspects of QoL were observed over time, including global health status (QL), physical functioning (PF), role functioning (RF), emotional functioning (EF), social functioning (SF), as well as symptoms such as fatigue, pain, dyspnoea, and insomnia (all p < 0.05). There was also significant change in all 5 aspects of EQ-5D-5L and utility score over time. Overall, most improvements in functional and symptom scales were observed in the first 3-6 months’ follow-up. Among the 241 patients with at least 3 months’ follow-up, compared to those without druggable mutations, those with druggable mutations demonstrated better QL at 3- and 12-month (mean difference (MD) 6.11, p=0.04; MD 19.56, p=0.01, respectively), PF at 3-, 6-, and 12-month (MD 12.76, p=0.001; MD 14.62, p=0.01; MD 22.55, p=0.02), EF at 12-month (MD 21.76, p = 0.001), and SF at 6- and 12-month (MD 14.51, p=0.02; MD 21.86, p=0.04); improved pain at 6- and 12-month (MD 14.44, p = 0.03; MD 36.57, p = 0.02), dyspnoea at 3-month (MD 18.23, p<0.001) and appetite at 6-month (MD 15.23, p = 0.04). They also had higher utility scores at 3- and 6-month intervals (MD 0.13, p = 0.04; MD 0.23, p = 0.05).
Conclusions
In conclusion, this study demonstrated improvements in QoL and symptom relief in newly diagnosed stage IV NSCLC patients within the first 3-6 months in Hong Kong. Patients with druggable mutations generally experienced better QoL compared to those without.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Hong Kong.
Funding
Roche.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract